Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

November 2022

AGC Biologics Receives Excellence in Innovation and Leadership by Italy's Leading Business News Channel Le Fonti

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based within the OpenZone campus, announced it received the Excellence in Innovation and Leadership Award from Italy’s leading business new channel, Le Fonti.

The company was honored for the work of its Milan site, which helps produce cell and gene therapy treatments for Biotech companies for clinical and commercial applications.


The ceremony was held at the prestigious location Palazzo Mezzanotte, seat of the Italian Stock Exchange, and saw AGC Biologics awarded the Excellence in Innovation and Leadership prize in the Healthcare sector for the leadership position in the Cell & Gene Therapy sector, its deep technical excellence and the critical work of the R&D department focused in bringing innovative platforms and solutions to the market.

AGC Biologics Milan offers end-to-end services for cell therapy and viral vector development and manufacturing. The facility was also the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has industry-unique commercial manufacturing experience. Since joining the AGC Biologics Global network in 2020, AGC Biologics invested in innovations to expand its capabilities and manufacturing capacity. The scientists at AGC Biologics Milan have several decades of experience guiding advanced therapy products through key product stages, including developing three commercial products.